Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
32 results about "Transgenic Rats" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Transgenic rats are rats that have foreign DNA inserted into their genome. This means one or more genes from a non-rat organism (i.e. human, fish, plant or jellyfish) has been added, through some tricks of modern molecular biology, to every one of a trangenic rat’s cells.
Method for establishing humanized rat drug evaluation animal model
InactiveCN104593418AVector-based foreign material introductionAnimal husbandryLarge fragmentEngineered genetic
The invention provides a method for establishing a humanized rat drug evaluation animal model. According to the method, a multidrug resistance gene 1 (Abcb1)-knocked-out genetically engineered rat is obtained through a microinjection method by virtue of a CRISPR / Cas9 gene knockout technology and 153kb bacterial artificial chromosome (BAC) fragments containing a humanized Abcb1 promoter and cDNA is simultaneously inoculated into the rat genome through the microinjection method by virtue of a large fragment transgenic technology to obtain a transgenic rat capable of stably expressing human Abcb1 and the genetically engineered rat and the transgenic rat are hybridized to establish the humanized rat drug evaluation animal model. RT-PCR analysis shows that Abcb1 expression profiles of humanized Abcb1 rat are significantly different from those of the rat endogenous Abcb1. The method has the beneficial effects that the humanized rat capable of expressing human Abcb1 is obtained and the rat is used for expressing human Abcb1 genes and has closer expression profiles to those of human so that the model can be well used for the efficacy evaluation of newly developed drugs.
Owner:INST OF LAB ANIMAL SCI CHINESE ACAD OF MEDICAL SCI
Method for producing transgenic rats
ActiveUS20080134352A1Organic active ingredientsPeptide/protein ingredientsBiotechnologyGenetically modified animal
Owner:CALIFORNIA INST OF TECH
Genetically Modified Rat Models for Cancer
ActiveUS20100287628A1Nucleic acid vectorVector-based foreign material introductionProgenitorHuman cancer
This invention relates to the engineering of animal cells, preferably mammalian, more preferably rat, that are deficient due to the disruption of tumor suppressor gene(s) or gene product(s). In another aspect, the invention relates to genetically modified rats, as well as the descendants and ancestors of such animals, which are animal models of human cancer and methods of their use.
Owner:TRANSPOSAGEN BIOPHARM
Use of crispr/cas9 as in vivo gene therapy to generate targeted genomic disruptions in genes bearing dominant mutations for retinitis pigmentosa
PendingUS20160324987A1Cell receptors/surface-antigens/surface-determinantsPeptide/protein ingredientsDiseaseIn vivo
Described herein are methods and compositions for genomic editing. Clustered regularly interspaced short palindromic (CRISPR) allows for highly selective targeting and alteration of genetic loci. Here, the Inventors demonstrate CRISPR as capable of being used in living animals to prophylactically prevent a genetic disease from manifesting. Targeting and disruption of mutated rhodopsin gene prevents progression of retinitis pigmentosa in the retinal cells of a transgenic rat model. Such techniques allow for treatment methods in subjects with dominant genetic mutations, often associated with lack of a gene product, or a toxic gene product. The described technology effectively abrogates deleterious effects due to the presence of a mutated gene copy allowing the normal function of the wild-type protein to prevent cell and vision loss. The efficacy of these in vivo mechanisms are widely extensible to similar dominant negative gene mutations causing disease, or other types of genetic disease.
Owner:CEDARS SINAI MEDICAL CENT
Transgenic rat as animal model for human huntingdon's disease
InactiveUS20070044162A1Lower metabolismReduced CMRGGlcBiocideGenetic material ingredientsHuntingtons choreaTherapeutic effect
Huntington's Disease (HD) is an autosomal-dominant inherited progressive neurodegenerative disease from the group of CAG repeat / polyglutamine diseases and is characterized by a triad of psychiatric alterations, dementia and motor dysfunction. On a sub-cellular level, a mutation with extended CAG tri-nucleotide repeats has been identified as the cause of HD. The therapeutic effects of certain substances can be tested on neurotoxically-induced or transgenic animal models with expanded CAG-repeats. In the present invention, transgenic rats were generated and characterized for human HD. Said rat model for human HD and other diseases of the CNS carries 51 CAG repeats under the control of a rat promoter and has a slow progressive neurological phenotype, closely reflecting human HD syndrome. The comparability of the rat model in relation to human HD is characterized by neuropathological, neuroradiological and neurochemical modifications accompanied by typical behavioral symptoms.
Owner:RIESS OLAF +1
Transgenic animal
A transgenic rat containing in its genome a nucleotide sequence encoding a Ga subunit protein, which Ga protein subunit is uncoupled from regulation by Regulators of G-Protein Signaling (RGS) proteins, which Gx subunit protein is eventually the dominant-negative G188S mutant of Gax9, which nucleotide sequence is operatively associated with a neuron-specific expression control sequence, wherein the transgenic rat expresses the GA subunit protein in neural cells resulting in extended D-protein coupled receptor signaling mediated by the Ga subunit protein.
Owner:WYETH LLC
Genetically Modified Rat Models for Pharmacokinetics
The present invention provides a desired rat or a rat cell which contains a predefined, specific and desired alteration rendering the rat or rat cell predisposed to drug transport sensitivity or resistance drug transport resistance or sensitivity. Specifically, the invention pertains to a genetically altered rat, or a rat cell in culture, that is defective in at least one of two alleles of a drug transporter gene such as the Slc7a11 (NC_005101.2) gene, the Abcb1 (NC_005103.2) gene, etc. The present invention also provides a desired rat or a rat cell which contains a predefined, specific and desired alteration rendering the rat or rat cell predisposed to drug transport sensitivity or resistance drug transport resistance or sensitivity. Specifically, the invention pertains to a genetically altered rat, or a rat cell in culture, that is defective in at least one of two alleles of a drug transporter gene.
Owner:TRANSPOSAGEN BIOPHARM
Transgenic rats and spermatogonial stem cells
A transgenic rat expresses a gene of interest, such as EGFP, exclusively in the germ cells of both males and females. From such a transgenic rat one can isolate a line of spermatogonial stem cells, which can renew and proliferate in culture.
Owner:TEXAS SYST BOARD OF REGENTS UNIV OF
Genetically modified rat models for pharmacokinetics
InactiveUS20150052623A1Compound screeningCell receptors/surface-antigens/surface-determinantsRat modelDrug transport
Owner:OSTERTAG ERIC M +1
Genetically Modified Rat Models for Severe Combined Immunodeficiency (SCID)
This invention relates to the engineering of animal cells, preferably mammalian, more preferably rat, that are dencient due to the disruption of tumor suppressor gene(s) or gene product(s). In another aspect, the invention relates to genetically modified rats, as well as the descendants and ancestors of such animals, which are animal models of human cancer and methods of their use.
Owner:HERA TESTING LAB INC
Genetically Modified Rat Models for Drug Metabolism
The present invention provides a desired rat or a rat cell which contains a predefined, specific and desired alteration rendering the rat or rat cell predisposed to alterations in drug and chemical metabolism by modification of its structure or mechanism. Specifically, the invention pertains to a genetically altered rat, or a rat cell in culture, that is defective in at least one of two alleles of a drug metabolism gene such as the Cyp7b1 gene, the Cyp3a4 gene, etc. In another embodiment, the rat cell is a somatic cell. The inactivation of at least one drug metabolism allele results in an animal with a higher susceptibility to altered drug and chemical metabolism. In one embodiment, the genetically altered animal is a rat of this type and is able to serve as a useful model for altered drug and chemical metabolism or toxicology and as a test animal for autoimmune and other studies. The invention additionally pertains to the use of such rats or rat cells, and their progeny in research and medicine. In one embodiment, the invention provides a genetically modified or chimeric rat cell whose genome comprises two chromosomal alleles of a drug metabolism gene wherein at least one of the two alleles contains a mutation, or the progeny of the cell.
Owner:TRANSPOSAGEN BIOPHARM
Genetically Modified Rat Models for Pain
This invention relates to the engineering of animal cells, preferably mammalian, more preferably rat, that are deficient due to the disruption of gene(s) or gene product(s) resulting in altered nervous system function. In one aspect, the altered function results in pain in the mammal. In another aspect, the nervous system dysfunction results in prolonged hyperalgesia, allo dynia, and loss of sensory function. In another aspect, the invention relates to genetically modified rats, as well as the descendants and ancestors of such animals, which are animal models of altered nervous system function mediated pain and methods of their use. In another aspect, the genetically modified rats, as well as the descendants and ancestors of such animals, are animal models of nervous system dysfunction resulting in prolonged hyperalgesia, allodynia, and loss of sensory function and methods of their use. In another aspect, the present invention provides a method of identifying a compound useful for the treatment or prevention of pain.
Owner:TRANSPOSAGEN BIOPHARM
Model rat with the onset of prostatic cancer
To provide a rat model with the onset of prostate cancer in which the prostate cancer including an invasive cancer can be developed and can be bred for generations stably. A rat model with the onset of prostate cancer which can develop prostate cancer including invasive cancer and can be bred for generations stably is established by: ligating an SV40 large T antigen gene onto the downstream of rat probasin gene promoter; the resulting PBSVT transgene is introduced into a fertilized egg of a Sprague-Dawley rat; after the introduction, the fertilized egg is transplanted into a recipient rat; a transgenic rat obtained from the recipient rat is then mated with a wild-type Sprague-Dawley rat; the transgenic offspring rats thus obtained are similarly can be bred for generations thereafter; and transgenic rats developing prostate cancer are selected through histopathological observation of the prostate.
Owner:JAPAN SCI & TECH CORP
Genetically modified rat models for severe combined immunodeficiency (SCID)
This invention relates to the engineering of animal cells, preferably mammalian, more preferably rat, that are deficient due to the disruption of tumor suppressor gene(s) or gene product(s). In another aspect, the invention relates to genetically modified rats, as well as the descendants and ancestors of such animals, which are animal models of human cancer and methods of their use.
Owner:HERA TESTING LAB INC
Transgenic animal
Owner:WYETH LLC
Genetically Modified Rat Models for Cytokine-Cytokine Signaling Pathways
The present invention relates to the engineering of animal cells, preferably mammalian, more preferably rat, that are deficient due to the disruption of gene(s) or gene product(s) resulting in cytokine-cytokine mediated autoimmune and inflammatory disease. In another aspect, the invention relates to genetically modified rats, as well as the descendants and ancestors of such animals, which are animal models of human autoimmune and inflammatory disease and methods of their use. Specifically, the invention pertains to a genetically altered rat, or a rat cell in culture, that is defective in at least one of two alleles of a cytokine gene such as the Faslg gene, the Fas gene, etc. In one embodiment, the cytokine gene is the Faslg gene. In another embodiment, the cytokine gene is one of several known cytokine genes, such as Fas, IFNγ, TNF-α, IL-2, IL-10, and IL-12. The inactivation of at least one of these cytokine alleles results in an animal with a higher susceptibility to cytokine-cytokine mediated autoimmune and inflammatory disease induction. In one embodiment, the genetically altered animal is a rat of this type and is able to serve as a useful model for cytokine-cytokine mediated autoimmune and inflammatory disease and as a test animal for autoimmune and other studies.
Owner:TRANSPOSAGEN BIOPHARM
Genetically Modified Rat Models for Obesity and Diabetes
InactiveUS20140041063A1Compounds screening/testingMicrobiological testing/measurementGene ModificationRat model
This invention relates to a genetically modified or chimeric rat cell whose genome comprises chromosomal alleles of an obesity-diabetes gene (especially, the Mc4r gene or Lep gene), wherein at least one of the two alleles contains a mutation, or the progeny of this cell. The obesity or diabetes gene may affect any of the pathways of obesity and diabetes. The obesity or diabetes gene may predispose the rat to a phenotype of obese and diabetic, lean and diabetic, obese and non-diabetic, non-obese and diabetic or any of the combinations thereof. In another aspect, the invention relates to a desired rat or a rat cell which contains a predefined, specific and desired alteration rendering the rat or rat cell predisposed to obesity or diabetes.
Owner:TRANSPOSAGEN BIOPHARM
Anti-OX40 fully human antibody and preparation method and application thereof
Owner:CURON MACAO LTD
Transgenic rat with human normal type c-Ha-ras gene
InactiveUS6576811B1Compounds screening/testingBiological testingAbnormal tissue growthC-Ha-ras Genes
The present invention provides a human c-Ha-ras proto-oncogene transgenic rat and the methods of the screening of many carcinogens and the screenings of promoters of carcinogenesis and preventive and inhibitory agents of tumors, and additionally enables the analysis of the carcinogenesis mechanism of a number of tumors.
Owner:NAT CANCER CENT RES INST +1
Transgenic rats and spermatogonial stem cells
A transgenic rat expresses a gene of interest, such as EGFP, exclusively in the germ cells of both males and females. From such a transgenic rat one can isolate a line of spermatogonial stem cells, which can renew and proliferate in culture.
Owner:TEXAS SYST BOARD OF REGENTS UNIV OF
Model of alzheimer's disease
InactiveUS20160081312A1Synergistic effectReduce riskCompounds screening/testingHeavy metal active ingredientsCellular modelApoptosis
The invention features a non-transgenic rat model for early AD, using a metal mixture of As, Cd and Pb, characterized by enhanced synergistic amyloidogenicity in rat cortex and hippocampus. This model can serve as a tool for (a) AD-directed drug screening, and (b) determining mechanism of AD pathogenicity. It features induction of the A?-mediated apoptosis and induction of inflammation in rodent brain. The invention features novel astrocyte and neuronal cellular models for AD, using a metal mixture of As, Cd and Pb, characterized by enhanced synergistic amyloidogenicity. This model can serve as a tool for (a) AD-directed drug screening in astrocytes and neurons, and (b) determining mechanism of AD pathogenicity in cells. It features induction of the A?-mediated apoptosis and induction of inflammation in astrocytes and neurons.
Owner:COUNCIL OF SCI & IND RES
Genetically modified rat models for pain
This invention relates to the engineering of animal cells, preferably mammalian, more preferably rat, that are deficient due to the disruption of gene(s) or gene product(s) resulting in altered nervous system function. In one aspect, the altered function results in pain in the mammal. In another aspect, the nervous system dysfunction results in prolonged hyperalgesia, allodynia, and loss of sensory function. In another aspect, the invention relates to genetically modified rats, as well as the descendants and ancestors of such animals, which are animal models of altered nervous system function mediated pain and methods of their use. In another aspect, the genetically modified rats, as well as the descendants and ancestors of such animals, are animal models of nervous system dysfunction resulting in prolonged hyperalgesia, allodynia, and loss of sensory function and methods of their use. In another aspect, the present invention provides a method of identifying a compound useful for the treatment or prevention of pain.
Owner:TRANSPOSAGEN BIOPHARM
Genetically modified rat models for drug metabolism
Owner:TRANSPOSAGEN BIOPHARM
Fully human antibody against ox40 and its preparation method and use
The present application provides fully human monoclonal antibodies directed against member 4 of the tumor necrosis factor receptor superfamily (TNFRSF4), also known as OX40 and CD134. The present application also provides a method for producing hybridomas using humanized transgenic rats, nucleic acid molecules encoding anti-OX40 antibodies, expression vectors and host cells for expressing anti-OX40 antibodies. The invention also provides methods for validating antibody function in vitro and antibody efficacy in vivo. The antibodies of the present invention provide very effective agents for the treatment of various cancers by modulating human immune function.
Owner:CURON MACAO LTD
Method for separating rat hypothalamic arcuate nucleus neurons
PendingCN114276993AAchieve separationReduce dependencyNervous system cellsIndividual particle analysisNucleusNeuronal nuclei
The invention discloses a method for separating rat hypothalamic arcuate neurons. The method comprises the following steps: finding out a plurality of markers with most significant differential expression of arcuate neuron nuclei in hypothalamus; according to the expression difference of the markers in other cell populations, screening out unique markers with significant high expression in the arcuate nucleus region, wherein the markers are respectively Gck, S100g, Six6 and Sox14; positive cells containing four markers Sox14, S100g, Gck and Six6 in hypothalamus are sorted by adopting flow cytometry, and the concentration of arcuate nucleus neuron nuclei in the obtained positive cell population is relatively high; based on a space transcriptome technology, separation is realized through flow cytometry sorting, so that the separation of the arcuate nucleus neuron nuclei is realized; according to the method for separating the hypothalamic arcuate nucleus neuron nuclei, transgenic rats do not need to be cultured, the operation cost is low, the dependence degree on instruments and platforms is low, and the method is suitable for being popularized and popularized in research and development institutions.
Owner:上海昆盟生物科技有限公司
Model animal with overexpression of regucalcin
InactiveUS7355093B2Avoid problemsResearch expensiveNervous disorderMetabolism disorderCDNA libraryMale pronucleus
The present invention provides an animal model which overexpresses regucalcin, a calcium-binding protein that is inherently expressed in the liver and the like of the higher animal, and which is characterized by a showing of bone pathology typified by osteoporosis. When regucalcin expression is lowered, it induces other physiological abnormalities. In the present invention, cDNA encoding the full length of regucalcin protein was cloned from a rat liver cDNA library, ORF was cut out, and introduced into an expression vector (pCXN2). The pCXN2 gene expression vector containing ORF cDNA was microinjected into the male pronucleus of a fertilized egg of rat which was subsequently transplanted into the uterine tube of a host rat to generate transgenic rats homozygous for regucalcin. The transgenic rats are characterized by remarkable bone pathology, morphologically as well as biochemically, and by significant suppression of body weight gain, and are therefore useful for screening of preventive and therapeutic agents related to bone diseases.
Owner:JAPAN SCI & TECH CORP
Immortalized vascular adventital cell line
Owner:JAPAN SCI & TECH CORP
Immortalized vascular adventital cell line
To provide an immortalized capillary pericyte line which maintains the original function / property of the cell line-deriving tissue, its establishment method, and the screening method for useful substance using the immortalized capillary pericyte line. Cerebral tissue of a transgenic rat carrying the large T antigen gene of SV40 thermo-sensitive mutant line tsA58 is homogenized and the resultant brain capillaries are treated with protease, thus obtained brain capillary cells are subcultured to establish an immortalized cell that expresses SV40 thermo-sensitive large T antigen, PDGF receptor beta, and Angiopoietin-1. In addition, the immortalized vascular pericyte line has ability to deposit calcium on matrix by dense culture.
Owner:JAPAN SCI & TECH CORP
A high-efficiency cleaning device for drinking water bottles of transgenic mice
ActiveCN112439760BRealize automatic batch cleaningReduce labor intensityHollow article cleaningCleaning using liquidsBiotechnologyBristle
Owner:WEST CHINA HOSPITAL SICHUAN UNIV
Construction method and application of transgenic rat specifically expressing hmrgprx4
Owner:HEPAITECH (BEIJING) BIOPHARMA TECH CO LTD
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com